secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evommune, Inc. (EVMN)
CIK:        0002044725
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-211934
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evommune reports Q1 net loss $21.7M; EVO756 Phase 2b data due June 2026 in CSU
------------------------------------------------------------------------------

- Net loss $21.7M in Q1 2026 vs $14.6M prior year; cash, equivalents and investments $307.0M as of March 31, 2026.
- EVO756 Phase 2b top-line data in chronic spontaneous urticaria expected June 2026; atopic dermatitis data in Q3 2026.
- Phase 2b dose-ranging trial for EVO756 in migraine prophylaxis to start mid-2026; top-line data anticipated in 2027.
- EVO301 Phase 2b atopic dermatitis trial planned for mid-2027 after positive Phase 2a proof-of-concept data in February 2026.
- Revenue zero vs $3.0M prior year (Maruho collaboration ended); R&D expenses $17.3M, G&A $6.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526211934/0001193125-26-211934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2044725/000119312526211934/evmn-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-211934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer